After AI express, some investors ask on the investor interaction platform: is Omicron rampant, whether the orders and sales of relevant products of the company have increased greatly, and can the production capacity keep up with the demand
Acrobiosystems Co.Ltd(301080) (301080. SZ) said on the investor interaction platform on January 30 that in 2021, the company will accelerate the response speed to covid-19 virus mutant strain and develop high-standard and high-quality antibodies, antigens, kits and other products in a short time for global scientific research and industrial customers to help fight the epidemic. The company expects that the sales revenue of covid-19 virus epidemic prevention related products in 2021 will be 87-97 million yuan, with a year-on-year increase of 20% – 33%. The planning department of the company forecasts the demand according to the historical sales situation, order demand and market data, formulates the production plan and issues the production task accordingly, and meets the market demand through reasonable goods preparation and timely expansion of production capacity.
